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Abstract: Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease, and
environmental factors are proposed to exacerbate existing symptoms. One such environmental
factor is mercury. The aim of this study was to investigate the relationship between exposure to
mercury (Hg) and disease activity and disease associated damage in Total Hg concentrations in hair
and urine were measured in 52 SLE patients. Dental amalgams were quantified. Disease activity was
assessed using three indexes including the British Isles Lupus Assessment Group Index (BILAG).
Disease associated damage was measured using the Systemic Lupus International Collaborating
Clinics/American College of Rheumatology SLICC/ACR Damage Index. Pearson’s correlation
identified a significant negative correlation between hair Hg and BILAG (r = ´0.323, p = 0.029) and
SLICC/ACR (r = ´0.377, p = 0.038). Multiple regression analysis identified hair Hg as a significant
predictor of disease associated damage as determined by SLICC/ACR (β = ´0.366, 95% confidence
interval (CI): ´1.769, ´0.155 p = 0.019). Urinary Hg was not related to disease activity or damage.
Fish consumption is the primary route of MeHg exposure in humans and the inverse association of
hair Hg with disease activity observed here might be explained by the anti-inflammatory effects of
n-3 long chain polyunsaturated fatty acids also found in fish.
Keywords: mercury; lupus; disease activity
1. Introduction
Identification of environmental risk factors that stimulate the development of systemic lupus
erythematosus (SLE) in genetically susceptible individuals has been the focus of considerable
research [1]. The potentially modifiable nature of some of these environmental factors makes this
a particularly attractive area of research and presents an opportunity to impact lupus disease activity
and subsequent morbidity. Mercury (Hg) is an environmental factor that has been suggested to be
associated with the development of SLE [2], albeit the evidence is limited [3].
Hg exists as elemental Hg, inorganic (iHg) or organic (e.g., MeHg) compounds. Humans
encounter elemental Hg primarily through inhalation of Hg vapour (Hg0) from dental amalgams
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or through exposure to atmospheric Hg0 directly (industrial emissions) [4]. Most inhaled Hg0
is absorbed in the lungs and subsequently converted to iHg within the body. Environmental
exposure to iHg occurs principally from ingested (non-fish) food, with minor contributions from fish
consumption and drinking water. Methylation of iHg to methylmercury (MeHg) by aquatic bacteria
and subsequent bio magnification up the aquatic food chain, results in the bioaccumulation of organic
MeHg in fish [5]. Fish consumption is the primary route of MeHg exposure in humans. The US
environmental protection agency (EPA) reports a reference dose (RfD) level for methylmercury of
0.1 µg per kilogram of body weight per day [6]. The mean hair Hg concentration in a cohort of
adult American females in the general population was 0.47 ppm [7] and typical urine Hg levels in an
American male population that had amalgams were 3.1 ug/L [8]. In some areas of high exposure to
industrial pollution (i.e., the mercury poisoning that occurred at Minamata), hair Hg concentrations
have reached concentrations of 705 ppm [9]. The no observed adverse effect level for hair mercury is
50 ppm, whilst for pregnant individuals this is lowered to 10 ppm [10].
Both in vitro and in vivo studies have demonstrated the ability of various Hg species to cause
damage and dysfunction to a number of physiological systems including the immune system. In vitro
studies report that both iHg and MeHg exposures result in decreased cell proliferation capacity [11],
dysregulation of pro- and anti-inflammatory cytokine balance [12–14] and increased lymphocyte
apoptosis [15]. Changes observed in cytokine production have been suggested to drive responses of
autoreactive T cells towards the development of autoimmunity [16,17]. Animal studies consistently
demonstrate that both iHg and MeHg exposure induces systemic autoimmunity in those who are
genetically susceptible [18–21] and exacerbates autoimmune symptoms in animal models which
spontaneously develop lupus like disease [22]. Furthermore, studies report acceleration in the
development of autoantibodies and immune complex (IC) deposits following organic Hg (oHg)
treatment in models of idiopathic autoimmunity [23].
Epidemiological studies have reported that increased exposure to Hg0, owing to an individual’s
exposure to industrial Hg0 pollution, is linked with an increased prevalence of SLE [2,24,25].
The immunotoxic effects of chronic low level exposure to Hg0 in humans has been postulated to
be associated with an increased risk of developing lupus [26] and scleroderma [27]. Occupational
exposure of Hg0 has been associated with increased concentrations of autoimmune anti-nuclear
autoantibodies by some [28,29] whereas others have not observed any association [30–32].
Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) describes an
autoimmune/inflammatory disease which develops in response to exposure to a component
that contains an adjuvant [33]. Although limited, research to date suggests that Hg (both MeHg and
Hg0) exposure in certain individuals elicits a syndrome similar to ASIA [34]. However, no study has
investigated Hg exposure in SLE using biomarkers and clinical endpoints. Therefore, the aim of this
study was to investigate the relationship between Hg exposure measured in hair (biomarker of MeHg
exposure), urine (biomarker of Hg0 exposure), and dental amalgam status (indirect biomarker of Hg0
exposure) and clinically determined disease activity and disease associated damage in SLE patients.
2. Materials and Methods
2.1. Study Design
Participants were identified through rheumatology clinics in the Belfast Health and Social Care
Trust (BHSCT) and Western Health and Social Care Trust (WHSCT), Northern Ireland. Participants
were recruited as part of a larger study that assessed the relationship between vitamin D status
and disease activity [35]. All participants met the criteria for diagnosis of SLE as defined by the
American College of Rheumatology (ACR) criteria [36]. Ethical approval was obtained from the
Office of Research Governance Northern Ireland (10/NIR02/43) and all participants provided written
informed consent. The research adhered to the standards outlined in the Declaration of Helsinki 1975
(revised Hong Kong 1989).
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2.2. Clinical Assessment
The assessment of disease activity and damage was performed by one of two consultant
rheumatologists experienced in the use of clinical assessment tools in the research setting. Participants
were evaluated for disease activity using the British Isles Lupus Assessment Group Index (BILAG),
Systemic Lupus Activity Measure (SLAM), the revised Safety of Estrogen in Lupus Erythematosus
National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity
Index (SLEDAI), and disease associated damage was assessed using the SLICC/ACR damage index.
All disease indices and samples were collected on the same day.
BILAG uses subjective and objective measures to assess the extent to which an organ system
is contributing to disease activity over the previous 4 weeks. Each organ system is assigned a
grade based on disease activity [37]. A cumulative numerical BILAG score was calculated using the
collective grades from each organ system [37]. SLICC/ACR+ determines disease associated damage
that has occurred after diagnosis of SLE. Symptoms are required to be present for at least 6 months.
The score range is 0–47 [38]. SLAM evaluates 11 organ systems and considers 30 variables, a score
of 7+ is considered clinically significant and distinguishes active disease from periods of remission
and parameters spanning the previous 30 days are measured [39,40]. SELENA-SLEDAI considers
symptoms over the previous 30 days and contains 3 components that evaluate new disease activity,
the deterioration of an existing ailment, increases or decreases in medication and the physician’s
global assessment visual analogue scale score. A score of 4+ indicates active disease [41]. Disease
activity measures have been shown to correlate with each other in clinical trials, but the precise
measures will vary within and between patients. In using all 3 SLE disease activity measures along
with a measure of damage we will be able to investigate recent and cumulative effects of Hg exposure.
Serological Measures
Blood samples in serum separator tubes were centrifuged for 15 min at 3000 g. An aliquot
of serum was analysed for anti-double stranded DNA antibodies, C3 and C4 at the Royal
Victoria Hospitals Belfast immunology labs which is a member of the UKNEQAS scheme for
nuclear and related antigens. Venous blood was collected into a trisodium citrate tube for the
measurement of erythrocyte sedimentation rate (ESR). ESR was measured using the Westergren
method. The fluorescence enzyme linked immunoassay (Phadia, Immunocap 250) was utilised for
detection of anti-dsDNA. Plasmid dsDNA was coated to a solid phase support. Serum samples were
diluted 1/10 and incubated for 30 min. Secondary antibodies and washing steps were automated.
C3 and C4 were quantified by rate nephleometry (Beckman Image 8000).
2.3. Urine and Hair Collection
Hair samples were taken from participants who consented to having their hair cut.
Approximately 50–100 strands of hair were held between the finger and thumb near the base of the
scalp of each patient. The hair was then clamped with a haemostat and cut with surgical scissors
as close to the scalp as possible by the researcher. Samples were then tied firmly with cotton thread
1–2 cm from the cut end before the haemostat was released. Hair samples were then placed in a
labelled envelope to be stored at room temperature. The closest 1 cm of hair to the head was then
analysed using cold vapour atomic absorption spectrometry for total Hg. A 30 mL fasted urine
sample (second morning void) was collected and stored at ´80 ˝C and subsequently analysed for
total mercury using atomic fluorescence spectrometry.
2.4. Anthropometric Assessment
Body weight (kg) was measured to the nearest 0.1 kg using portable scales (Seca; Brosch Direct
Ltd., Peterborough, UK). Height (m) was measured to the nearest 0.1 cm using a stadiometer (SECA,
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Model 220, Hamburg, Germany). Body mass index (BMI) was calculated as weight (kg) divided by
height squared (m2).
2.5. Urinary and Hair Mercury Assessment
Hair and urine samples were shipped to the University of Rochester, Rochester, NY, USA, for Hg
analysis. Hair Hg concentrations were determined using cold vapour atomic absorption and the
“Magos” reagents and method [42]. MeHg is the predominant form of Hg that exists in hair. Hg below
the limit of detection (<0.75 ppm) was imputed as 0.75/2 ppm [43]. Urine samples were assessed
for total Hg concentrations (ng/mL) by atomic fluorescence spectrometry (PSA 10.035 Millennium
Merlin, PS Analytical Ltd., Kent, United Kingdom) by methods used previously [44]. Assessment of
Hg within the urine reflects inorganic Hg, primarily from dental amalgams [9]. The accuracy of the
methods was assessed in all analyses by including standard reference materials for hair (IAEA-085
and IAEA-086, International Atomic Energy Agency) and urine (Seronorm, SERO AS, Stasjonsvn,
Norway). The Mercury Laboratory at the University of Rochester participates in external quality
assessment for mercury analyses through participation in the Interlaboratory Comparison Program
for Metals in Biologic Matrices (Institut National de Santé Publique, Quebec, Canada). The University
of Rochester Mercury Analytical Laboratory served as a Reference Laboratory for analysis of hair
for the recent quality assessment of laboratories within the transnational COPHES/DEMOCOPHES
project [45]. Urinary Hg concentrations were normalised by adjusting with creatinine concentration
(µmol/L) as measured by the ILAB 650 (SpA, Milan, Italy). The intra assay precision coefficient of
variance (CV) for creatinine was <1.7%.
2.6. Quantification of Dental Amalgams
Participants were provided with a mirror in order to self-report the quantity of their own dental
amalgams. All amalgams were given a score of 1 regardless of their size or location. Patients also
provided information on the removal and replacement of any previous dental amalgams.
2.7. Statistical Analysis
Statistical analysis was undertaken using IBMr SPSSr Statistics v20. Similar to previous studies
the distribution of Hg concentrations (hair and urine) was skewed [46], while disease indexes and
serological measures were also skewed and thus these parameters were log transformed for plotting
and analysis. Results are presented using the mean (˘SD) on their natural scale.
The primary aim was to investigate for associations between hair Hg or urinary Hg and measures
of disease activity and disease associated damage. Correlation analysis was used to determine
associations between hair Hg and disease activity and disease associated damage, and also between
urinary Hg concentration and disease activity and disease associated damage. Pearson’s correlation
was used to assess the relationship between each of the disease activity and disease associated
damage indexes. Standard multiple regression analysis was carried out to determine the strength
of the relationship between Hg in both hair and urine, and disease activity and disease associated
damage. Model 1 was statistically adjusted for the potential influence of age. Model 2 was adjusted
for age and BMI. Standard multiple regression analysis was used to determine the relationship
between the serological measures (anti-dsDNA, C3, C4, and ESR) and mercury exposure, whilst
controlling for age and BMI.
Secondary analysis was carried out to investigate the association between dental amalgam count
and disease activity and disease associated damage and to determine if there is a difference in Hg
concentrations (hair and urine) between those with active disease and those with inactive disease.
Independent t-tests were used to test for differences in mean hair Hg and urinary Hg concentration
between those with active and inactive disease.
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3. Results
3.1. Study Population
The patient’s characteristics are detailed in Table 1. The mean (˘SD) age of the 52 SLE patients
in this study was 48 (˘13.19) years with a mean BMI of 27 (˘4.96) kg/m2. Some 94.2% of patients
were female. The mean (˘SD) disease activity and disease associated damage scores were BILAG
6.1 (˘6.29), SLAM 5.66 (˘2.39), SELENA SLEDAI 4.46 (˘4) and SLICC/ACR 0.96 (˘1.12). SLAM
identified 13 out of 52 (25%) of patients to be currently suffering from a disease flare (score > 7), whilst
SELENA SLEDAI identified one patient (score > 6). Mean (˘SD) hair and urine Hg concentrations
were 1.50 (˘1.55) ppm and 1.1 (˘1.24) ng/g creatinine, respectively. The mean (˘SD) number of
dental amalgams was 4.9 (˘4.6) surfaces and the average number removed was self-reported to be
0.8 (˘1.9), bringing the total amalgams ever installed to an estimated average of 5.6 (˘5.4) surfaces.
Pearson’s correlation showed that BILAG correlated with SLAM and SLICC (p ď 0.001, p = 0.010,
respectively) SLAM correlated with SLICC (p = 0.020), whilst SELENA SLEDAI did not correlate
with any other index.
Table 1. Characteristics of systemic lupus erythematosus patients.
Mean (˘SD)
N = 52
Age 48 (˘13.19)
Gender—Female (%) 50 (96.2%)
BMI 27 (˘4.96)
Smoker, n (%) 9 (17.3%)
Taking immunosuppresants, n (%) 7 (13.5%)
Taking steroids, n (%) 12 (23.1%)
Anti-DsDNA antibody iu/mL 23.2 (˘42.7)
Anti-DsDNA positive, n (%) 16 (30.8%)
ESR mm/h 15.2 (˘18.04)
C3 g/L 1.09 (˘0.31)
C4 g/L 0.21 (˘0.14)
SLAM 5.66 (˘2.39)
SELENA SLEDAI 4.46 (˘4)
BILAG 6.1 (˘6.29)
SLICC/ACR 0.96 (˘1.12)
Neurological involvement, n (%) 5 (9.6%)
Renal involvement, n (%) 4 (7.7%)
Urine Hg ng/g creatinine 1.1 (˘1.24)
Hair Hg ppm 1.5 (˘1.55)
Dental amalgams 4.9 (˘4.6)
Anti-DsDNA antibody: anti double stranded DNA antibody; BILAG: British Isles Lupus Assessment Group
index; BMI: Body mass index; C3: Complement 3; C4: Complement 4; ESR: erythrocyte sedimentation rate;
Hg: mercury; SELENA SLEDAI: Safety of Estrogen in Lupus Erythematosus National Assessment Systemic
Lupus Activity Index; SLAM: Systemic Lupus Activity Measure; SLE: Systemic Lupus Erythematosus;
SLICC/ACR: Systemic Lupus International Collaborative Clinics/American College of Rheumatology.
3.2. Univariate Correlations
A significant negative correlation was observed between hair Hg and BILAG (r = ´0.323;
p = 0.029) but not with SLAM (r = ´0.25; p = 0.093) or SELENA SLEDAI (r = 0.300; p = 0.843). Hair
Hg was negatively correlated with SLICC ACR (r = ´0.377; p = 0.038) (Table 2). Urinary Hg did not
significantly correlate with any measure of disease activity or disease associated damage.
Secondary analysis found no relationship between the quantity of dental amalgams and any
measure of disease activity or disease associated damage. Number of dental amalgams present
correlated positively with urine Hg concentration (r = 0.541, pď 0.001) but not with hair Hg (Table 3).
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3.3. Multiple Regression Analysis
The degree to which Hg predicts disease activity and disease associated damage was estimated
by standard multiple regression (Table 3). Table 2 shows a significant inverse correlation between
hair Hg and BILAG; however, as shown in Table 3, this association was no longer significant after
controlling for age and BMI. Hair Hg was not a significant predictor of any other measure of
disease activity.
Table 2. Correlation between markers of Hg exposure and disease activity and damage in SLE (n = 52).
Markers of Hg
Exposure
BILAG SLAM SELENA SLEDAI SLICC ACR
r p r p r p r p
Hair Hg ´0.323 0.029 * ´0.251 0.093 0.105 0.843 ´0.377 0.038 *
Urine Hg ´0.081 0.592 ´0.078 0.605 ´0.023 0.895 0.182 0.226
Dental Amalgams 0.222 0.274 0.253 0.086 ´0.218 0.136 ´0.032 0.830
BILAG; British Isles Lupus Assessment Group index; Hg: mercury; SELENA SLEDAI: Safety of Estrogen in
Lupus Erythematosus National Assessment Systemic Lupus Activity Index; SLAM: Systemic Lupus Activity
Measure; SLE: Systemic Lupus Erythematosus; SLICC/ACR: Systemic Lupus International Collaborative
Clinics/American College of Rheumatology. Statistical analysis was performed using Pearsons correlation.
* denotes significance p < 0.05.
Table 3. The relationship between urine and hair Hg and measures of disease activity and damage in
SLE (n = 52).
Model PredictorVariables
BILAG SLAM
Model
R2 p Value (95% CI) Beta
Model
R2 p Value (95% CI) Beta
1
Hair Hg 0.111 0.062 ´0.189, 0.105 ´0.088 0.065 0.096 ´3.250, 0.273 ´0.088Age 0.569 ´0.189, 0.105 ´0.088 0.752 ´0.048, 0.067 0.05
2
Hair Hg
0.111
0.066 ´.884, 0.293 ´0.294
0.127
0.131 ´3.057, 0.411 ´0.238
Age 0.571 ´0.191, 0.107 ´0.088 0.697 ´0.45, 0.067 0.06
BMI 0.928 ´0.378, 0.345 ´0.013 0.091 ´0.020, 0.253 0.252
1a
Urine Hg 0.02 0.621 ´6.250, 3.774 ´0.188 0.007 0.614 ´2.398, 1.434 ´0.12Age 0.449 ´0.200, 0.090 ´0.116 0.89 ´0.59, 0.052 ´0.12
2a
Urine Hg
0.02
0.629 ´6.399, 3.910 ´0.076
0.057
0.808 ´2.152, 1.687 ´0.037
Age 0.323 ´0.203, 0.092 ´0.116 0.974 ´0.056, 0.054 ´0.021
BMI 0.988 ´0.401, 0.395 ´0.002 0.141 ´0.038, 0.258 0.229
SELENA SLEDAI SLICC ACR
1
Hair Hg 0.031 0.586 ´2.242, 4.078 ´0.267 0.021 0.019 * ´1.769, ´0.155 ´0.366Age 0.258 ´0.159, 0.044 ´0.186 0.263 ´0.012, 0.041 0.173
2
Hair Hg
0.057
0.506 ´2.115, 4.223 ´0.238
0.147
0.015 * ´1.823, ´0.204 ´0.385
Age 0.28 ´0.157, 0.047 0.177 0.281 ´0.012, 0.040 0.166
BMI 0.301 ´0.120, 0.378 0.16 0.256 ´0.100, 0.027 ´0.165
1a
Urine Hg 0.264 0.821 ´1.126, 1.412 0.33 0.182 0.234 ´0.351, 1.4 0.184Age 0.081 ´0.069, 0.004 ´0.263 0.939 ´0.024, 0.026 0.012
2a
Urine Hg
0.266
0.791 ´1.132, 1.477 0.04
0.203
0.288 ´0.418, 1.375 0.165
Age 0.088 ´0.070, 0.005 ´0.26 0.973 ´0.25, 0.026 0.005
BMI 0.797 ´0.088, 0.114 0.039 0.558 ´0.089, 0.049 ´0.091
BILAG: British Isles Lupus Assessment Group index; BMI: body mass index; CI: confidence intervals;
Hg: mercury; SELENA SLEDAI: Safety of Estrogen in Lupus Erythematosus National Assessment; Systemic
Lupus Activity Index; SLAM: Systemic Lupus Activity Measure; SLE: Systemic Lupus Erythematosus;
SLICC/ACR: Systemic Lupus International Collaborative Clinics/American College of Rheumatology.
Statistical analysis was performed using standard multiple regression. * denotes significance p < 0.05.
Hair Hg was not a significant predictor of any measure of disease activity. Hair Hg was a
significant inverse predictor of disease associated damage (β = ´0.366, p = 0.019; 95% confidence
interval (CI): ´1.769, ´0.155) and explained 2% of the variation in disease associated damage as
measured by SLICC ACR. Further analysis controlling for BMI identified that hair Hg explained
«15% of the variation in disease associated damage (β = ´0.385, p = 0.015, 95% CI: ´1.823, ´0.204).
Regression analysis identified that urinary Hg did not significantly predict disease activity or disease
associated damage.
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Neither Hair Hg nor urinary mercury were significantly related to serological markers, except
ESR, which was inversely related to hair Hg (β = ´0.297, p = 0.05, 95% CI: ´0.531, ´0.001). When
controlling for age and BMI no relationship existed between any serological markers and indices of
Hg exposure.
3.4. Hg Concentrations in Those with Active Disease versus Inactive
Participants were classified as active or inactive according to each disease activity measure.
As shown in Figure 1, those with an active disease status according to SLAM (n = 14) had a
significantly lower hair Hg (0.7 ppm) than those who had an inactive disease (n = 38) (1.75 ppm,
p = 0.009). There was no significant difference between hair Hg in those with active disease (n = 6)
(1.2 ppm) compared to those with inactive disease (n = 46) (1.69 ppm) as determined by BILAG, albeit
this approached significance (p = 0.062). SELENA SLEDAI identified one patient as suffering from
active disease; therefore no analysis was completed. No differences in urinary Hg concentrations
were observed between those with active disease and those who were classified as inactive (Figure 1).
Figure 1. Hair mercury levels in systemic lupus erythematosus patients stratified by disease activity
(SLAM) using 7+ as a cut off. Error bars indicate the SEM. * denotes significance p < 0.05.
4. Discussion
A significant inverse relationship was observed between hair Hg and disease associated damage
as measured by SLICC/ACR, although we observed no relationship between hair Hg, and disease
activity. Furthermore no association was observed between disease activity or disease associated
damage and urinary Hg or number of dental amalgams. Those with inactive disease had significantly
higher hair Hg concentrations than those with active disease as determined by SLAM.
Results from this study would indicate that higher concentrations of Hg in the hair are predictive
of decreased disease associated damage in SLE. Although not significant the results are suggestive of
a trend between disease activity (BILAG & SLAM) and hair Hg and are supported by the finding that
patients in remission have significantly higher hair Hg than patients with active disease. BILAG is
the most detailed assessment of disease activity followed by SLAM and both assess changes deemed
to be clinically significant over the previous month.
Hair Hg consists mostly of MeHg and represents the previous month’s exposure to MeHg.
All fish bio-accumulate MeHg and dietary fish consumption is the principal exposure route for
MeHg in humans [5]. Fish are also a rich source of long chain n-3 polyunsaturated fatty acids
(LCPUFA) and previous work by us and others has identified LCPUFA ingestion as having a positive
influence on disease activity in SLE [47,48]. Furthermore, research investigating the relationship
between healthy maternal MeHg exposure and markers of neurological child development has
reported an inverse relationship between MeHg and cognitive function [49], which is attributed to
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the beneficial effects of LCPUFAs from fish consumption [50]. The anti-inflammatory properties of
n-3 LCPUFA result from their ability to act as a substrate for the production of anti-inflammatory
eicosanoids. The n-3 LCPUFA can also modify inflammatory gene expression via peroxisome
proliferator-activated receptors (PPARs) to skew cytokine profiles towards an anti-inflammatory
state [51]. Fish also contain α-tocopherol and carotenoids, which are potent scavengers of free
radicals. In addition, fish are a major contributor to selenium intake and selenium has been linked
with a range of health benefits including improved immune function, decreased risk of cardiovascular
disease and protection against certain forms of cancer [52]. Therefore, in this study, it is plausible that
hair Hg is acting as a surrogate marker for fish consumption and the nutrients present in fish are
eliciting a beneficial effect on the SLE patients health. This possibility is supported by findings from
the National Health and Nutrition Examination Survey (NHANES) 1999–2004, which reported that
Hg exposure was associated with ANA positivity and adjusting for n-3 fatty acid status increased the
magnitude of the association [53].
Another possible explanation for the apparent protective effect of a higher hair MeHg
concentration on disease associated damage observed in this study is that MeHg is acting as
an immunosuppressive [20]. Previous animal and ex vivo studies have reported MeHg to
reduce immunoglobulin response following a challenge with an immunogen [54], as well as
decreasing proliferation response [15,55]. Therefore, it is plausible that MeHg may be acting as an
immunosuppressant and reducing disease associated damage.
Autoimmune diseases, including SLE, have been linked with exposure to dental amalgams [56];
yet the scientific evidence for such a link is lacking. Similar to others, we observed that urinary Hg
correlated with the number of dental amalgams in the SLE patients [57], and thereby suggesting that
urine Hg is a good biomarker of Hg0 exposure in this population. Urinary Hg concentrations were
relatively low (1.1 ng/g creatinine) in comparison to occupationally exposed cohorts (3.67 ng/mL
(unadjusted for creatinine)) [46] but higher than a non-occupationally exposed healthy cohort
(0.46 ng/g creatinine) [58]. The absence of an association between urinary Hg and disease activity
or disease associated damage suggests that Hg0 exposure, at the low concentrations observed in
this study, is not related to disease status. Similarly no association exists between disease outcomes
and the quantity of dental amalgams present. These findings may be owing to the low levels of
iHg exposure, although previous research has suggested that biologically relevant doses of HgCl2
can cause autoimmunity in predisposed animals [22]. The majority of animal studies conducted to
date have used concentrations higher than humans would normally encounter [18,19,22]. To our
knowledge this study is the first to analyse Hg exposure in SLE patients and the finding that neither
MeHg or Hg0 exposure impacts negatively on disease outcomes has important implications for public
health advice given to patients. These findings contribute important information regarding the safety
of dental amalgam use, particularly in patients with autoimmunity.
A limitation of this study is that we have no measure of fish intake or fatty acid profile which
would aid in the interpretation of these results. Habitual Hg exposure (MeHg and Hg0) is unknown
as the sample was taken at one time point only. Speciation of hair samples would further improve the
interpretation of these results. The use of hair as a marker of MeHg exposure is imperfect as total hair
Hg does not consist entirely of MeHg. Hair Hg may contain ethyl Hg encountered in vaccines [59]
but we did not record any detail on vaccine use in this study. Vaccines have been implicated in the
development of ASIA syndrome [33]. As hair Hg in this study was relatively low it is unclear how
exposure to high dose MeHg would interact with disease activity and disease associated damage in
SLE. An increased sample size would have allowed sub analysis comparing Hg exposure in those
with specific disease manifestations such as renal and central nervous system involvement.
5. Conclusions
This study provides evidence that low dose Hg0 exposure from dental amalgams is not
associated with disease activity or disease associated damage in SLE. It is postulated that the inverse
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correlation observed between hair Hg and disease associated damage is confounded by unmeasured
nutritional covariates such as LCPUFA status. Future research would benefit from the collection of
dietary data to assess fish intake along with a measure of serum LCPUFA.
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